Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Denali Therapeutics Inc.
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
IPO Date: December 8, 2017
Sector: Healthcare
Industry: Biotech
Market Cap: $2.06B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.80 | 2.76%
Avg Daily Range (30 D): $0.33 | 2.27%
Avg Daily Range (90 D): $0.41 | 2.93%
Institutional Daily Volume
Avg Daily Volume: .55M
Avg Daily Volume (30 D): 1.2M
Avg Daily Volume (90 D): 1.2M
Trade Size
Avg Trade Size (Sh.): 68
Avg Trade Size (Sh.) (30 D): 75
Avg Trade Size (Sh.) (90 D): 74
Institutional Trades
Total Inst.Trades: 3,136
Avg Inst. Trade: $2.76M
Avg Inst. Trade (30 D): $2.45M
Avg Inst. Trade (90 D): $2.23M
Avg Inst. Trade Volume: .1M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $3.78M
Avg Closing Trade (30 D): $3.2M
Avg Closing Trade (90 D): $3.01M
Avg Closing Volume: 134.24K
   
News
Apr 2, 2025 @ 12:00 PM
Denali Therapeutics Announces Initiation of BLA Fi...
Source: N/A
Feb 18, 2025 @ 6:00 PM
Mucopolysaccharidosis Market Analysis Across 7MM Ã...
Source: Delveinsight
Feb 13, 2025 @ 6:00 PM
Alpha-Synuclein Inhibitors Clinical Trial Pipeline...
Source: Delveinsight
Feb 11, 2025 @ 8:48 AM
Neuroregeneration Therapy Market to Surpass USD 64...
Source: Transparency Market Research
Aug 1, 2024 @ 4:25 PM
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guida...
Source: Zacks Equity Research
Financials
  TTM Q1 2025 Q3 2024
Basic EPS $-.78 $-.63
Diluted EPS $-.78 $-.63
Revenue $ $ M $ M
Gross Profit $ $ $
Net Income / Loss $ $ -132.97M $ -107.19M
Operating Income / Loss $ $ -145.58M $ -123.19M
Cost of Revenue $ $ $
Net Cash Flow $ $ -116.48M $ 15.96M
PE Ratio